Polypeptides

PreclinicalSmall molecule

RRyazan State Medical University

Polypeptides is one of 44 small molecule programs targeting Atherosclerosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AtherosclerosisActive, not recruiting

AtherosclerosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

52 competitors in Atherosclerosis

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Approved

7 2

Niacor

AbbVie

Approved

6 3

Crestor

AstraZeneca

Approved

5 4

Praluent

Regeneron

Approved

5 5

Plavix

Sanofi

Approved

3 6

Aldactone

Pfizer

Approved

2 7

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

10 8

Onglyza

AstraZeneca

Approved

1 9

Selzentry

GSK

Approved

1 10

Actos

Takeda

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atherosclerosis1 trial

Efficacy and Safety of the Regulatory Polypeptides in Patients With Peripheral Atherosclerosis.

Recruiting·RRyazan State Medical University·N/A·NCT05933720·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Polypeptides. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Polypeptides compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Polypeptides. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ryazan State Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RRyazan State Medical University

Polypeptides

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atherosclerosis1 trial

References

Drug Info

Quick Facts

Related News